AstraZeneca expects US vaccine data ‘soon’ — with 50M doses ready by the end of April
AstraZeneca said it’s readying the release of data from its US-based Phase III trial, which has more than 32,000 participants, for its upcoming emergency use authorization application.
“We expect data from our US Phase III trial to be available soon, in the coming weeks, and we plan to file for emergency use authorization shortly thereafter,” a company spokesperson said via email.
A snap decision on the vaccine would put the US months behind the EU in authorizing it, but recent concerns about blood clots pushed Norway, Denmark and Iceland to halt the vaccine’s use. The European Medicines Agency, however, noted, “As of 9 March 2021, 22 cases of thromboembolic events had been reported among the 3 million people vaccinated with COVID-19 Vaccine AstraZeneca in the European Economic Area.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.